| 1.0 | Definitions |
|-----|-------------|

|   | 1.1 | ‘Agreement’      means this Master Service Agreement (MSA) and any of the Project-Specific      Addenda (PSA) and Work Orders executed by both parties in writing and      attached thereto. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.2    | Clinical Study/Trial:      Any investigation in human subjects intended to discover or verify the      clinical, pharmacological and/or other pharmacodynamic effects of an      Investigational Product(s), and/or to identify any adverse reactions to an      Investigational Product(s), and/or to study absorption, distribution,      metabolism, and excretion of an Investigational Product(s) with the object      of ascertaining its safety and/or efficacy. The terms “Clinical Trial” and      “Clinical Study”      are synonymous. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|   | 1.3    | ‘Confidential      Information’ means any and all information which is now or at any time      hereafter in the possession of one party and which is disclosed (whether      orally or in any material form) to the other party or of which the other      party becomes aware and which relates to the general business or financial      affairs or Intellectual Property Rights of the disclosing party, including      without limitation, information relating to the Services, the Materials,      the Protocol, data, databases, know-how, formulae, processes, designs,      photographs, drawings, specifications, prices, results, software programs      and samples and any other material bearing or incorporating any      information relating to the disclosing party’s business, business affairs,      products, employees, consultants, contractors and marketing      information. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

|   | 1.4 | Regulations for Good Clinical      Practice: Order # 266 of the Ministry of Healthcare of the Russian      Federation “On the enactment of the Clinical Practice rules in the Russian      Federation” as of 19 June 2003, Federal Law as of 12 April 2010      # 61-FZ “On Medical Drugs”, National Standard GOST R 52379-2005 of the      Russian Federation (approved by the Order of the Federal Agency of      Technical Harmonization and Metrology), identical to the ICH GCP –      Guidelines for Good Clinical Practice of the International Conference on      Harmonization of Technical Requirements for Registration of      Pharmaceuticals for Human Use (Note for guidance on Good Clinical Practice      (CPMP/ICH/135/95)). |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.5    | ‘Intellectual      Property Rights’ means any and all industrial property rights, including      patents, know-how, trade marks (whether registered or unregistered),      design rights (whether registered or unregistered), utility models,      applications for and rights to apply for any of the same, rights to      prevent passing off, copyright, database rights, topography rights and any      other rights in any invention, discovery or process in any jurisdiction in      the world. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|        | 1.6    | Materials means      compound(s) or medical devices and documents as referred to in the      Protocol and provided to OCT to enable it to perform the Services under      this MSA. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                |

|  | 1.7 | ‘Protocol’      means the clinical trial protocol and other protocols if required,      describing the objective(s), design, methodology, statistical      considerations and organization of the Clinical  Trials. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page      1 of 10 | Adherex:      _________ |

----

|   | 1.8 | Monitoring: The act of      overseeing the progress of the Clinical Study, and of      ensuring that it is conducted, recorded, and reported in accordance with      the Protocol, Standard      Operating Procedures, Regulations for Good Clinical Practice, and      the Applicable      Regulatory Requirements. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.9 | Services means services      on organization and carrying out of the Clinical Trial, as further      specified in the Work Orders attached to this  MSA. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.10 | ‘Product’      – the Investigational product |
|--------|------|----------------------------------------------------------------|

|   | 1.11 | Sponsor      – a legal entity which takes responsibility for the initiation and/or      management and financing of the Clinical Study; the developer and/or owner      of the Product; the company Adherex. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.0 | Scope      of Agreement |
|-----|-------------------------|

|   | 2.1 | ОСТ agrees to      perform at the request of Adherex tasks with regard to the organization      and monitoring of the Clinical trial, gathering and processing data,      regulatory and the logistical activities connected with implementation of      the services to the extent described in detail in the PSAs and Work Orders      hereto, being the exhibits to the Agreement and forming its integral part.      The Clinical trial will be carried in the territory of the Russian      Federation. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.1 | This      MSA forms the basis for a working relationship between Adherex and OCT. This      Agreement will be supplemented, in the form of PSAs and Work Orders, as      the need arises. The PSA or the Work Order will contain the detailed      requirements for the Services that are contracted to  OCT. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.0 | OCT      Obligations and Rights |
|-----|---------------------------------|

|   | 3.1 | ОСТ undertakes to      perform the Services under the Protocol, the terms of this MSA, in      accordance with GCP and pursuant to the applicable local      regulations. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.2 | OCT      has the necessary contracted consultants with the capability, skills and      expertise to carry out the services set forth in the PSA in accordance      with the Protocol, GCP and all other relevant laws, regulations and      guidelines. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.3 | OCT      agrees to provide to Adherex regular reports on      the services performed and the status of the ongoing  trial. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------|

|   | 3.4    | OCT      agrees to offer assistance of any kind in professional, organizational and      administrative issues as well as in any other aspects relating to conduct      of the Clinical Trial. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                           |

|   | 3.5    | OCT      agrees to provide the delivery of the investigational product to the      Investigation Sites. Amount of the Product and order of the shipment of      the Product to the Investigation Sites will be agreed upon by the Parties      additionally, after OCT submits and Adherex approves the elaborated      Protocol. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                              |

|   | 3.6 | Project      Team. Stanislav Linkevich will serve as Project Manager for the duration      of the trial unless Mr. Linkevich employment is terminated with OCT or      Adherex is not satisfied with Mr. Linkevich's performance. Irina Petrova      will serve as Project Supervisor for the duration of the trial unless Ms.      Petrova's employment is terminated with OCT or Adherex is not satisfied      with Ms. Petrova's performance. Any change in key project team members,      (e.g. Project Manager/Supervisor or CRAs) will be approved by      Adherex. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page 2 of 10 | Adherex:      _________ |

----

|   | 3.7    | OCT      undertakes to return to Adherex all Materials      provided earlier by Adherex after the end of the Clinical Trial.      Adherex shall      cover the expenses connected with the return of the    Materials. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                             |

|   | 3.8 | OCT      shall have the right to require from Adherex any additional information      necessary to perform the Services under this MSA. In case the required      information is not provided or provided not in full, OCT shall have the      right to postpone the Services under thisMSA. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.0 | Adherex Obligations      and Rights |
|-----|------------------------------------------|

|   | 4.1    | Adherex shall provide all      the required documents on the basis of which OCT shall conduct the      Clinical Trial. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                        |

|   | 4.2    | Adherex      shall ensure the on-time supply of the product and other relevant      medicines and Materials to be used in the Clinical Trial as per the study      protocol. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                         |

|   | 4.3    | Adherex      shall ensure the timely response to any enquiry of OCT for any additional      documents necessary for the performance of the services under this      Agreement. The service performance in the part connected with the      requested Materials may be put on hold for the time period from the date      of inquiry till the date of Materials receipt. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                    |

|   | 4.4    | Adherex is responsible for      the on time wire transfer to the account of OCT amount of the payments for      the Services. Adherex shall be responsible      for the on-time wire transfers of the investigators’ and sites’ fee and      other pass-through-costs payments. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                  |

|   | 4.5 | Adherex      may request from the Service Provider any information related to the      Services under this MSA. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------|

| 5.0 | Compensation |
|-----|--------------|

|   | 5.1 | The      Total cost of the MSA is stated in the PSA which should be considered the      integral part of the Agreement. Changes in scope may be incorporated into      this Agreement upon the written consent of both parties provided that both      parties agree on any additional costs associated with the performance of      the changed Services. Agreement regarding changes in scope should be      agreed upon in writing before the work is  performed. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.2 | Due      to the specific nature of the following Services: Drug import, Ongoing      Regulatory submissions, Protocol Amendments, SAE and SUSAR submission and      inability to know the possible number of units may occur, the Parties      agree that the cost of one unit shall be stated in the PSA. Shall there be      more than one unit of the services performed, any and all such services      shall be invoiced at the factual occurrence of units, provided that such      services are preliminary approved by Adherex. These shall not be      considered as the increase of the total cost of the MSA. Corresponding      pass-through expenses for the abovementioned activities also will be      invoiced to Adherex on actualbasis. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.3 | All      additionally required services will respectively cause increase in the      total cost of the services. |
|--------|-----|------------------------------------------------------------------------------------------------------------------|

|   | 5.4 | In      the event of conflict between the terms of this Agreement and the Work      Order the terms of this MSA shallprevail. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------|

|   | 5.5 | The      Services rendered by OCT under this MSA will be paid for by Adherex on the      basis of the invoices issued by OCT in the course of the Service      performance under this Agreement. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.6 | Adherex      will reimburse OCT for reasonable expenses (PTCs) with appropriate      supporting documentation incurred by OCT in the performance of Services at      the rates specified in the PSA. Travel costs incurred as a result of      monitoring the trial should adhere to OCT’s travel guideline /      policy. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page 3 of 10 | Adherex:      _________ |

----

|   | 5.7 | The      Parties hereby agree that the PTCs estimation in the PSA Budget enclosed      does not include the expenses that can’t be foreseen before the start of      the work. Any and all such expenses shall be subject to the approval of      Adherex and will be invoiced in accordance with additional agreements      between parties. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.8 | All      fees/costs in the PSA Budget enclosed are net charges and all applicable      taxes like Custom duty on import of drugs, VAT, service tax, taxes from      PTCs, goods and services tax, if any, would be charged    extra. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.0 | Invoicing      and payment procedure |
|-----|--------------------------------------|

|   | 6.1 | The      Parties hereby agree on the following invoicing procedure during the      course of the Service Rendering under thisMSA: |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------|

|   | 6.1.1 | The      invoices for the Services (excluding Warehouse) rendered within the      framework of the Clinical Trial will be invoiced at the fulfillment of the      milestones as set forth below: |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a) | Within      30 calendar days from the effective date of this MSA, Adherex agrees to      make an advance payment to OCT in the amount of 10% of the Total Service      cost. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | 5%      of the cost of the Services - upon all sites evaluated and approved by      Adherex. |
|--------|----|----------------------------------------------------------------------------------------------|

|   | c) | 10%      of the cost of the Services – after obtaining of regulatory      approval |
|--------|----|------------------------------------------------------------------------------------------|

|   | d) | 10%      of the cost of the Services – 25% patients  enrolled |
|--------|----|---------------------------------------------------------------------|

|   | e) | 5%      of the cost of the Services - 50% patients  enrolled |
|--------|----|--------------------------------------------------------------|

|   | f) | 5%      of the cost of the Services – 75% patients  enrolled |
|--------|----|--------------------------------------------------------------------|

|   | g) | 15%      of the cost of the Services – 100% patients  enrolled |
|--------|----|----------------------------------------------------------------------|

|   | h) | 5%      of the cost of the Services – 25% of patients completed treatment, case      report forms monitored and queriesresolved. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------|

|   | i) | 5%      of the cost of the Services – 50% of patients completed treatment, case      report forms monitored and queriesresolved. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------|

|   | j) | 10%      of the cost of the Services – 75% of patients completed treatment, case      report forms monitored and queriesresolved. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------|

|   | k) | 10%      of the cost of the Services – 100% of patients completed treatment, case      report forms monitored and queriesresolved. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------|

|   | l) | 5%      of the cost of the ServicesDatabaseLock |
|--------|----|-------------------------------------------------|

|   | m) | 5%      All Sites Closed |
|--------|----|--------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page 4 of 10 | Adherex:      _________ |

----

|   | 6.2 | The      service invoice will itemize the total number of hours and/or days applied      to the clinical trial during the period of the milestone      fulfillment. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.3 | The      invoices for the PTCs incurred within the framework of Service Performance      will be invoiced on monthly basis asfollows: |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------|

OCT will submit an invoice for servicesand PTCs incurred within the framework of service performance within theprevious month.

|   | 6.4    | Payment      of each invoice is due upon receipt by Adherex and is past due thirty (30)      calendar days from receipt of invoice. If Adherex has any valid reason      for disputing any part of the invoice supplied by OCT they will notify OCT      within fourteen (14) calendar days of receipt by Adherex, and if no such      notification is given the invoice will be deemed valid. The portion of      OCT’s invoice, which is not in dispute, will be paid in accordance with      the procedures set forth herein. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

|   | 6.5    | OCT      will provide confirmation documents for all project expenses incurred and      invoiced to Adherex except amounts specified in PSA as fixed. Fixed      amounts and translation cost will be invoiced without supporting      documentation. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                  |

|   | 6.6    | Adherex      agrees to make the advanced payments for the following PTCs, shall the      need arise: |
|--------|--------|------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                 |

|   | 6.6.1 | Purchase      of concomitant medication. In case advanced payment for purchase of the      concomitant medication is required by the vendor (the drug supplier,      Adherex agrees to pay expenses for purchase of the concomitant medication      within 14 (fourteen) working days from receipt of invoice from OCT,      provided that OCT will provide Adherex with request of forthcoming payment      and tentative payment date not later than 15 (fifteen) working days prior      to day of expected payment. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.6.2 | Customs      payments. Adherex agrees to make the advanced payments for the customs and      brokers’ fees. The invoices for such payments shall be paid within 14      (fourteen) working days of the receipt date by  Adherex. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.6.3 | Investigators’      fees and Study Sites’ fees. Adherex agrees to make the advanced payments      for investigators’ fees and study sites’ fees provided that OCT shall      submit an invoice with a detailed report on the services performed by the      investigators and the study sites. Such invoice shall be paid within 14      (fourteen) days within the receipt byAdherex. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.7 | For      any delays with the payments Adherex shall be charged a late fee of 1% of      the total amount overdue for each month of the  delay. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.8 | OCT      has the right to suspend work if payments remain outstanding on undisputed      invoices. |
|--------|-----|----------------------------------------------------------------------------------------------------|

|   | 6.9 | The      currency of the Agreement is USD. All the payments are to be made in      USD. |
|--------|-----|-----------------------------------------------------------------------------------------|

| 7.0 | Period      of the Agreement |
|-----|------------------------------|

|   | 7.1 | This      Agreement shall take effect on ______, 2010 and shall terminate on June      31, 2013 unless either terminated earlier or extended by the parties      pursuant to the terms of clause 8.0. of this  MSA. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page 5 of 10 | Adherex:      _________ |

----

|   | 7.2 | The      period of the Clinical Trial shall be specified in the Protocol. In case      the duration of the Clinical Trial is prolonged above the termination date      of this MSA stated in article 7.1., the MSA shall be considered prolonged      accordingly. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.3 | Adherex      acknowledges that the deadlines of the Clinical Trial and this MSA might      be postponed not due to the fault of OCT. Adherex agrees to postpone all      the deadlines for a time period equal to the duration of the delays that      may incur. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.0 | Termination |
|-----|-------------|

|   | 8.1 | For      a period of fourteen (14) days prior to the exercise of the termination      rights in clauses 8.2 or 8.3 below, the parties agree that there will be      full discussion at senior management level between Adherex and OCT to      discuss the relevant issues and to explore alternatives to      termination. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 8.2 | This      MSA or a PSA and/or Work Order may be terminated by either party by giving      thirty (30) days written notice to the other  party. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 8.3    | In      the event of termination by Adherex for reasons other than default by OCT,      Adherex shall pay all sums owing to OCT, but unpaid, for work performed to      date of receipt of termination notice, and all agreed and documentally      supported costs associated with the termination itself or with the      payments that OCT is committed to make for the invoices from its      subcontractors and partners that have not been billed at the moment of      Termination of the Agreement and are connected with the service      performance under this Agreement, including but not limited to the      expenses for the booked hotels and tickets, courier services, customs and      logistical expenses, all necessary payments to the medical      representatives, Investigators and the Institutions. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|   | 8.4 | Either      party shall be entitled forthwith to terminate this Agreement or any      PSA/Work Order by written notice to the other if that other is adjudged      insolvent or goes into liquidation (other than for bona fide      reconstruction) or has a receiver appointed over any of its property or      assets. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 8.5 | If      this Agreement is terminated, all WORK ORDERs in existence at the date of      termination shall also terminate unless the parties agree      otherwise. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 8.6 | In      the event of termination of this Agreement for any reason OCT shall      promptly return to Adherex all Information (including unused study drug)      provided to OCT or generated by OCT in connection with the provision of      the Services. On termination of this Agreement for any reason, OCT shall      only retain any Information to the extent and for the duration required by      any applicable law, and shall notify Adherex in writing before destroying      such Information. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.0    | Warranties |
|--------|------------|
|   |       |

|   | 9.1 | OCT      warrants to Adherex that the Services will be performed in accordance with      the standard of care usually and reasonably expected in the performance of      such services. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.2 | Adherex      warrants that it is the legal and beneficial owner and has full title and      interest in the Protocol and to the Materials, or is otherwise licensed to      use the Protocol and Materials, and that OCT’s performance of its      obligations under this Agreement, provided they are undertaken in      accordance with this Agreement and the Protocol and OCT’s use or      possession of the Materials for the purposes of this Agreement will not      infringe the rights (including the Intellectual Property Rights) of any      third party. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page 6 of 10 | Adherex:      _________ |

----

| 10.0 | Liabilities      and Indemnities |
|------|----------------------------------|

|   | 10.1 | Subject      to the provisions of clause 10.3 below, Adherex shall fully indemnify and      keep indemnified, OCT against any and all claims, liability, losses,      damage, costs and/or expenses of any nature (including, without      limitation, legal costs and expenses) incurred or suffered by OCT which      arise directly out of any allegation or claim that performance of the      Services in accordance with the terms of this Agreement by OCT constitutes      infringement of any third party Intellectual Property Rights (“IP      Claims”). |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.2 | Subject      to the provisions of clause 10.3 below, Adherex shall indemnify and hold      OCT harmless from any third party liability, expenses, costs (including      legal costs), suffered or incurred in connection with any claim, suit or      proceeding brought against OCT so far as it is based on a claim for      personal injury suffered by patients and directly resulting from the      performance of the Services (“InjuryClaims”). |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.3 | The indemnities set out in      Clauses 10.1 and 10.2 above shall only apply provided      that: |
|--------|------|--------------------------------------------------------------------------------------------------|

OCT, its Affiliates, their representatives or anysubcontractors;

OCT becomes aware of any suchmatters.

|   | 10.4 | OCT      shall cooperate with Adherex and its legal representatives in the      investigation and defense of any IP Claim or Injury Claim under this MSA.      In the event an IP Claim or Injury Claim is asserted, OCT may elect to      choose counsel independent from that representing Adherex, in which case      Adherex shall be responsible to reimburse to OCT any costs and expenses      associated with the IP Claim or Injury Claim including, but not limited      to, legal costs, expert fees and all related  costs. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.5 | OCT      shall indemnify and hold harmless Adherex as a result of a claim or claims      arising from any negligent act, error or omission committed by OCT or by      an employee of OCT or any person or organization acting on behalf of OCT,      when so acting, in the course of services or contractual obligations      undertaken by OCT. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.0 | Confidential      Information |
|------|-------------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page 7 of 10 | Adherex:      _________ |

----

| 12.0 | Medical      and Regulatory |
|------|-----------------------------|

|   | 12.1 | Both      parties shall promptly notify the other party of any governmental      regulatory inspections of which it becomes aware and which relate to the      project. OCT by no means will limit the right of Adherex to be present at      any such inspections. Adherex in accordance with this MSA may delegate OCT      the responsibility for preparation of answers to all questions aroused      during inspection. In such occasion Adherex will provide OCT with all      information necessary to prepare suchanswers. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 12.2 | Adherex      may designate representatives who shall, upon reasonable notice to OCT,      have access to and shall be permitted to review all documents,      information, data and/or Materials specifically related to the conduct of      the clinical trial under this MSA. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.0 | Independent      Contractor Status |
|------|------------------------------------|

|   | 13.1 | It      is understood and agreed that OCT is an independent contractor and will      not have any rights to any of Adherex’s benefits. OCT agrees to make any      payments or withholding required by the Inland Revenue, social security      and any related statutes orregulations. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 13.2 | It      is further understood that OCT is not an agent of Adherex and Adherex is      not an agent of OCT and neither party is authorized to bind the other      party with respect to any thirdparty. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.0 | Conflicts      of Interest |
|------|----------------------------|

|   | 14.1 | OCT      represents that there is no conflict of interest between performance of      this MSA and the performance of services by OCT for any other party. In      the event that OCT believes that there is any such conflict, or any such      conflict arises during the term of this MSA, OCT will immediately notify      Adherex, which may, at its sole discretion, immediately terminate this      Agreement without liability to OCT. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.0 | Force      Majeure |
|------|--------------------|

|   | 15.1 | Neither      party shall be liable for delay in performing or failure to perform      obligations under this Agreement if such delay or failure results from      circumstances outside its reasonable control (“Force Majeure”). In such      circumstances, the party affected by the event of Force Majeure shall      promptly notify the other party of the Force Majeure and shall take all      reasonable steps to mitigate itseffects. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 15.2 | Subject      to compliance with the provisions of clause 15.1 above, an incident of      Force Majeure shall not constitute a breach of this MSA and the time for      performance shall be extended accordingly; however, if it persists for      more than 30 days: |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a) | the      parties may enter into discussions with a view to alleviating its effects      and, if possible, agreeing on such alternative arrangements as may be      reasonable in the circumstances; or |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | the      party not in default may immediately, on notice to the other party,      terminate this MSA and the provisions of clause 8.0 shall      apply. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.0 | Notices |
|------|---------|

|   | 16.1 | Any      notice will be in writing and will be given by registered mail, return      receipt requested, or hand delivered to the other party at the address      given on this agreement or to such other address as may be substituted by      notice. If sent by mail, notice will be effective on the date of receipt.      Other communication may be by a variety of means including telephone, fax,      email, etc. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page 8 of 10 | Adherex:      _________ |

----

| 17.0 | General      Provisions |
|------|-------------------------|

|   | 17.1 | This      Agreement and the obligations of the parties shall be governed by and      construed in accordance with the governing law of USA. All controversies      on this agreement should be solved under the jurisdiction of the New York      City courts. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.2 | Neither      party may subcontract or assign any of its obligations or rights under      this MSA without the prior written consent of the other party, save that      each Party may assign its rights and/or obligations hereunder to any of      its Associated Companies. Save for such permitted assignees, no person who      is not a party to this agreement shall be conferred any rights under      it. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.3 | The      headings in this Agreement are for reference purposes only; they will not      affect the meaning or construction of the terms of this      Agreement. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.4 | If      any parts or part of this Agreement are held to be invalid, the remaining      parts of the Agreement will continue to be valid and      enforceable. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.5 | Any      action of any kind by either party arising out of this Agreement must be      commenced within one (1) years from the date the right, claim, demand, or      cause of action shall first arise. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.6 | This      Agreement contains the complete and exclusive understanding of the parties      with respect to the subject matter hereof. No waiver, alteration or      modification of any of the provisions hereof will be binding unless in      writing and signed by a duly authorized representative of the party to be      bound. Neither the course of conduct between the parties nor trade usage      will act to modify or alter the provisions of this    Agreement. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.7 | This      Agreement has been executed and signed in two counterparts, one for each      Party. The      counterparts have equal juridicalforce. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.0 | Exhibits |
|------|----------|

|   | 18.1 | This      MSA has the      following exhibits attached hereto and incorporated  herein: |
|--------|------|-----------------------------------------------------------------------------------------|

|   | 1. | EXHIBIT 1. - PSA to MSA_      Adherex – OCT Group LLC dd. ____,2010 |
|--------|----|---------------------------------------------------------------------------|

| 19.0 | Legal      Address and Banking Details of theparties |
|------|------------------------------------------------------|

|              | OCT:_________           |
|-------------------|-------------------------|
| Page 9 of 10 | Adherex:      _________ |

----

|               | OCT:_________           |
|--------------------|-------------------------|
| Page      10 of 10 | Adherex:      _________ |

----